- Home
- HCKT vs NMRA Comparison
HCKT vs NMRA Comparison
Compare HCKT & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HCKT | NMRA |
|---|---|---|
| Founded | 1991 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 284.4M | 311.3M |
| IPO Year | 1998 | 2023 |
Fundamental Metrics
Financial Performance| Metric | HCKT | NMRA |
|---|---|---|
| Price | $9.73 | $1.51 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $17.00 | $7.50 |
| AVG Volume (30 Days) | 338.3K | ★ 1.5M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.67% | N/A |
| EPS Growth | N/A | ★ 5.23 |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $285,862,000.00 | N/A |
| Revenue This Year | $2.55 | N/A |
| Revenue Next Year | $5.07 | N/A |
| P/E Ratio | $54.71 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.16 | $0.83 |
| 52 Week High | $23.72 | $3.65 |
Technical Indicators
Market Signals| Indicator | HCKT | NMRA |
|---|---|---|
| Relative Strength Index (RSI) | 43.17 | 42.24 |
| Support Level | $9.60 | $0.83 |
| Resistance Level | $14.49 | $1.72 |
| Average True Range (ATR) | 0.54 | 0.10 |
| MACD | -0.06 | -0.01 |
| Stochastic Oscillator | 29.25 | 9.09 |
Price Performance
Historical ComparisonAbout HCKT Hackett Group Inc (The).
The Hackett Group Inc is an IP platform-based Generative Artificial Intelligence (Gen AI) strategic consulting and executive advisory digital transformation firm. The Hackett Group provides dedicated expertise in Gen AI-enabled enterprise transformation services across the front, mid and back office areas, including its highly recognized Oracle, SAP, OneStream and Coupa implementation offerings. It operates in three segments Oracle Solutions, SAP Solutions, and Global S&BT. It generates the majority of its revenue from the Global S&BT segment in the United States.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.